China’s medicine regulator has ordered a ‍halt to the import, ​sale and usage of ‌a drug used to ​treat dementia associated with Alzheimer’s disease made by India’s Sun Pharmaceutical Industries, according to an announcement posted on Monday (January 26, 2026).

The National Medical Products ​Administration said a recent remote ⁠inspection found shortcomings in the company’s production processes, including in the ​prevention of ⁠contamination anfulfilmentd the quality management department’s fulfillment of duties.

The body banned the sale ‌of Sun Pharma’s rivastigmine hydrogen ‌tartrate capsules.

A spokesperson for Sun Pharma, India’s ‍largest drugmaker by revenue, did not immediately respond to ‍a request for comment.

In 2024, the U.S. Food and Drug Administration issued a warning letter to Sun Pharma alleging “significant violations” of “current good manufacturing practice” regulations for pharmaceuticals ⁠made at the same production site in ​India, according to the U.S. ⁠regulator’s website.

Rivastigmine capsules have been used as a dementia treatment in China, one study showed.